Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
AssigneeFive Prime Pharmaceuticals, Inc.
InventorsThomas Harding, W. Michael Kavanaugh
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
Claims22
A method of treating a cancer characterized by a ligand dependent activating mutation in FGFR2 in a subject, comprising administering a therapeutically effective amount of an FGFR1 ECD to the subject.
A method of administering an FGFR1 ECD to a subject in need thereof, comprising:
- (a) determining if tumor cells from the subject express a ligand dependent activating mutation in FGFR2;
- and
- (b) if the tumor cells do express the ligand dependent activating mutation in FGFR2, then administering a therapeutically effective amount of an FGFR1 ECD to the subject.
Dependencies are inferred from the claim text.